Table 3.
Current ongoing clinical trials for TIGIT-specific monoclonal antibodies or antagonist agents.
| Name of the compound | Mechanism of action | Study phase | Trial ID | Targeted population | Status |
|---|---|---|---|---|---|
| Elotuzumab (active comparator) + pomalidomide + dexamethasone | Anti-SLAMF7 + angiogenesis and myeloma cell growth inhibitor + binds to GCR | Phase I/II | ClinicalTrials.gov NCT04150965 |
Patients with relapsed refractory multiple myeloma who have relapsed after treatment with prior therapies | Recruiting |
| Relatlimab | Anti-LAG-3 | ||||
| Relatlimab + pomalidomide + dexamethasone | Anti-LAG-3 + angiogenesis and myeloma cell growth inhibitor + binds to GCR | ||||
| BMS-986207 | Anti-TIGIT | ||||
| BMS-986207 + pomalidomide + dexamethasone | Anti-TIGIT + angiogenesis and myeloma cell growth inhibitor + binds to GCR | ||||
| Tislelizumab + ociperlimab Tislelizumab |
Anti-PD-1 + anti-TIGIT Anti-PD-1 |
Phase II | ClinicalTrials.gov NCT04693234 |
Participants with previously treated recurrent or metastatic cervical cancer | Active, not recruiting |
| IBI939 (dose escalation) | Anti-TIGIT | Phase I | ClinicalTrials.gov NCT04353830 |
Subjects with advanced malignancies | Active, not recruiting |
| IBI939 + sintilimab (dose-escalation stage) | Anti-TIGIT + anti-PD-1 | ||||
| IBI939 + sintilimab (expansion stage) | Anti-TIGIT + anti-PD-1 | ||||
| Tislelizumab + ociperlimab | Anti-PD-1 + anti-TIGIT | Phase II | ClinicalTrials.gov NCT04732494 |
Participants with PD-L1 tumor area positivity ⩾10% unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma | Recruiting |
| Tislelizumab + placebo | Anti-PD-1 | ||||
| BGB-A1217 (ociperlimab) + tislelizumab | Anti-TIGIT + anti-PD-1 | Phase I | ClinicalTrials.gov NCT04047862 |
Patients with locally advanced and metastatic solid tumors | Recruiting |
| AB154 (domvanalimab) + AB122 (zimberelimab) |
Anti-TIGIT + anti-PD-1 | Early phase I | ClinicalTrials.gov NCT04656535 |
Patients with first or second recurrence of glioblastoma | Recruiting |
| COM902 | A TIGIT inhibitor | Phase I | ClinicalTrials.gov NCT04354246 |
Subjects with advanced malignancies | Recruiting |
| COM701 + BMS-986207 + nivolumab | PVRIG inhibitor + anti-TIGIT + anti-PD-1 | Phase I/II | ClinicalTrials.gov NCT04570839 |
Patients with advanced solid tumors | Recruiting |
| Tislelizumab + ociperlimab | Anti-PD-1 + anti-TIGIT | Phase III | ClinicalTrials.gov NCT04746924 |
The purpose of the study is to compare PFS between arm A (ociperlimab in combination with tislelizumab) and arm B (pembrolizumab in combination with placebo) as assessed by investigators according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) and to compare overall survival between arm A and arm B | Recruiting |
| Pembrolizumab + Placebo | Anti-PD-1 | ||||
| Tislelizumab + placebo | Anti-PD-1 | ||||
| Tiragolumab + atezolizumab | Anti-TIGIT + anti-PD-L1 | Phase III | ClinicalTrials.gov NCT04543617 |
Participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy | Recruiting |
| Tiragolumab (placebo) + atezolizumab | Placebo + anti-PD-L1 | ||||
| M6223 | Anti-TIGIT | Phase I | ClinicalTrials.gov NCT04457778 |
Participants with metastatic or locally advanced solid unresectable tumors | Active, not recruiting |
| M6223 + bintrafusp alfa | Anti-TIGIT + anti-PD-L1/TGF-β | ||||
| Tiragolumab + atezolizumab | Anti-TIGIT + anti-PD-L1 | Phase III | ClinicalTrials.gov NCT04294810 |
Participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected NSCLC, with no EGFR mutation or anaplastic lymphoma kinase translocation | Recruiting |
| Placebo + atezolizumab | Placebo + anti-PD-L1 | ||||
| Pembrolizumab + vibostolimab | Anti-PD-1 + anti-TIGIT | Phase I/II | ClinicalTrials.gov NCT04305054 |
Participants with advanced melanoma and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy | Recruiting |
| Pembrolizumab | Anti-PD-1 | ||||
| Pembrolizumab/quavonlimab (coformulation) | Anti-PD-1/anti-CTLA-4 | ||||
| Pembrolizumab/quanvonlimab (coformulation) + lenvatinib | Anti-PD-1/anti-CTLA-4 + multiple kinase inhibitor | ||||
| Pembrolizumab + quavonlimab + vibostolimab Pembrolizumab + quavonlimab + lenvatinib |
Anti-PD-1 + anti-CTLA-4 + anti-TIGIT Anti-PD-1 + anti-CTLA-4 + multiple kinase inhibitor |
Phase I/II | ClinicalTrials.gov NCT04305041 |
Participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available | Recruiting |
| Etigilimab + nivolumab | Anti-TIGIT + anti-PD-1 | Phase I/II | ClinicalTrials.gov NCT04761198 |
Subjects with locally advanced or metastatic solid tumors | Recruiting |
| Pembrolizumab + vibostolimab Pembrolizumab + V937 Pembrolizumab |
Anti-PD-1 + anti-TIGIT Anti-PD-1 + binds to intracellular adhesion molecule 1 Anti-PD-1 |
Phase I/II | ClinicalTrials.gov NCT04303169 |
Participants with stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available | Recruiting |
| Sasanlimab + encorafenib + binimetinib Sasanlimab + axitinib + SEA-TGT |
Anti-PD-1 + BRAF inhibitor + MEK inhibitor Anti-PD-1 + VEGFR1–3, c-Kit, PDGFR inhibitor + anti-TIGIT |
Phase I/II | ClinicalTrials.gov NCT04585815 |
Patients with NSCLC | Active, not recruiting |
| CRC01 + fludarabine + cyclophosphamide | Anti-CD19 CAR-T (PD-1 knockdown, TIGIT knockdown) + DNA synthesis inhibitor + cell apoptosis (DNA crosslinks both between and within DNA strands at guanine N-7 positions) | Phase I/II | ClinicalTrials.gov NCT04836507 |
Adult patients with relapsed or refractory large B-cell lymphoma | Recruiting |
| GPC3 and/or TGF-β targeting CAR-T cells | CD4+ T cells are genetically engineered to express TGFβ-CAR and secret IL-7/CCL19 and/or SCFVs against PD-1/CTLA-4/TIGIT, CD8+ T cells are constructed to express GPC3-DAP10-CAR with knockdown of PD-1/HPK1 | Phase I | ClinicalTrials.gov NCT03198546 |
Human hepatocellular carcinoma patients with GPC3 expression | Recruiting |
CAR-T, chimeric antigen receptor T; EGFR, epidermal growth factor receptor; LAG-3, lymphocyte activation gene-3; NSCLC, non-small-cell lung cancer; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival; TGF-β, transforming growth factor beta; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.